We report here anatomic variants which were found during a retrospective study of a male patient, 54 years old, evaluated in computed tomography: heptafurcation of the celiac trunk (CT) and bilateral double renal arteries. The seven branches of the heptafurcated CT were the (1) left and (2) right inferior phrenic arteries, the (3) splenic and (4) left gastric artery, the (5) common hepatic artery, further sending off the (a) proper, continued as left, hepatic artery and (b) the gastroduodenal artery, (6) a replaced right hepatic artery and (7) the dorsal pancreatic artery. To our knowledge, heptafurcation of the CT was not reported previously. The arterial variants have great importance during various surgical and interventional procedures and should be documented prior to respective procedures.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00276-018-1995-3 | DOI Listing |
ACS Appl Mater Interfaces
January 2025
Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing, Jiangsu 210094, China.
Uncontrolled bleeding and infection following trauma continue to pose significant clinical challenges. This study employs hemoadhican (HD) polysaccharide, known for its superior hemostatic properties, as the foundational material to synthesize antibacterial carbon dots (H-CDs) through a hydrothermal method at various temperatures. The H-CDs exhibiting optimal antimicrobial properties were identified via in vitro antimicrobial characterization.
View Article and Find Full Text PDFJ Hepatocell Carcinoma
January 2025
Department II of Interventional Radiology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, People's Republic of China.
Purpose: To assess the activity and toxicity of hepatic arterial infusion chemotherapy (HAIC)+tislelizumab+lenvatinib (HAIC+tisle+len) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) type IV (Vp4 hCC) in a real-world context.
Methods: Fifty-five patients, with Vp4 hCC receiving HAIC+tisle+len therapy from April 2021 to December 2022, were analyzed retrospectively. Data on patient characteristics, adverse events (AEs), treatment, and survival were collected.
Updates Surg
January 2025
Pancreatic and Endocrine Surgical Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
The presence of an aberrant right hepatic artery (a-RHA) could influence the oncological and postoperative outcomes after pancreaticoduodenectomy (PD). A comparative study was conducted, including patients who underwent PD with a-RHA or with normal RHA anatomy. The primary endpoints were R1 resection in all margins (pancreatic, anterior, posterior, superior mesenteric artery, and portal groove), overall survival (OS), and disease-free survival (DFS).
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: A growing number of centers offer hepatic artery infusion pump (HAIP) chemotherapy for advanced liver malignancies. While small series have demonstrated feasibility of robotic HAIP placement, comparison of outcomes with open placement is lacking. We compared outcomes after robotic versus open HAIP placement.
View Article and Find Full Text PDFCureus
December 2024
Medicine, Griffith University, Gold Coast, AUS.
The cystic artery is a critical anatomical landmark in both laparoscopic and open cholecystectomy. This report presents a unique case involving two rare anatomical variations: double cystic arteries, along with a superficial branch originating from the superior mesenteric artery (SMA) - a previously unreported combination with significant clinical and surgical implications. Unlike earlier studies, this research provides detailed anatomical and embryological insights supported by high-quality imaging and illustrations to guide surgeons in recognizing and managing this novel variation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!